Most Popular

    Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia  Type 2 (MacTel)

    Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel)

    LMRI would like to share the following press release from Neurotech Pharmaceuticals about the BLA for NT-501 as a treatement for MacTel: Cumberland, R.I., November 8, 2024 (BUSINESS WIRE) – Neurotech Pharmaceuticals, Inc., an innovator in sustained...

    Free community webinar about MacTel

    Free community webinar about MacTel

    November 14, 2024 The following information was sent out via email to people who registered in the LMRI Contact Database.   Neurotech has partnered with Prevent Blindness to sponsor an online event with a focus on MacTel Type 2.  This free webinar...

    Phase 3 Trial Currently Enrolling MacTel Patients

    Neurotech Pharmaceuticals, with support from the Lowy Medical Research Institute, is currently enrolling a Phase 3 clinical trial testing ciliary neurotrophic factor (CNTF) in patients with macular telangiectasia type 2.  This is a multi-center trial...

    MacTel Project 2021 Update

    MacTel Project 2021 Update

    LOWY MEDICAL RESEARCH INSTITUTE - LMRI This past year has surely been an interesting and challenging one.  We hope that you and your family, friends, neighbors, and coworkers were able to weather the events safely. Despite the many challenges prese...